Research programme: cancer therapeutics - Eli Lilly and Company
Alternative Names: DNA checkpoint project - ICOS; Research programme: cell cycle checkpoint/DNA repair inhibitors - ICOSLatest Information Update: 02 Aug 2019
At a glance
- Originator Array BioPharma; ICOS Corporation
- Developer Array BioPharma; Eli Lilly and Company
- Class
- Mechanism of Action Checkpoint kinase inhibitors; DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 30 Jun 2016 Eli Lilly and Company enters into an agreement with Regen BioPharma to initiate an Open Innovation Drug Discovery Program for the treatment of Cancer